Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,293 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer, Head and Neck Clear all
Recruiting Phase 3 Interventional

Head and Neck Cancer Study Project in the Geriatric Population

NCT06998069
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Arm I Carboplatin, Paclitaxel, Pembrolizumab, Arm II Carboplatin, Paclitaxel, Cetuximab, Arm III Pembrolizumab
Drug
Lead sponsor
Brown University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Completed No phase listed Observational

Predicting Tolerance to Radiation Therapy in Older Adults With Cancer

NCT01752751
View directory record Official record
Conditions
Pre-treatment Loss of Independent Activities of Daily Living
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 10, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

NCT00599131
View directory record Official record
Conditions
Cancer of Larynx
Interventions
Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis

NCT02399228
View directory record Official record
Conditions
Oral Mucositis
Interventions
0.25% EISO mouth rinse
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 10, 2026, 11:47 PM EDT
Terminated Early Phase 1 Interventional

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

NCT04630353
View directory record Official record
Conditions
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
HB-201 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Active, not recruiting Not applicable Interventional

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

NCT05053230
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Tumor, Thoracic Tumor, Thoracic Cancer, Gynecologic Cancer, Gynecologic Tumor, Melanoma, Ovarian Cancer
Interventions
IM@Home, Enhanced usual care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Active, not recruiting Phase 2 Interventional

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

NCT04831320
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma
Interventions
nab-paclitaxel, Nivolumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Completed No phase listed Observational

Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation

NCT01568723
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
response to therapy
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 10, 2026, 11:47 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

NCT05893888
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable)
Drug
Lead sponsor
Privo Technologies
Industry
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Duarte, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Active, not recruiting No phase listed Observational

Evaluation of Improved Onboard Patient Imaging

NCT06187103
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Interventions
HyperSight Imaging
Device
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

NCT03993353
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
Interventions
Pembrolizumab, Tadalafil
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Withdrawn Early Phase 1 Interventional

Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

NCT02442739
View directory record Official record
Conditions
Head and Neck Cancer, Pancreatic Cancer, Depression
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 10, 2026, 11:47 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of ALE.C04 in Patients With Head and Neck Cancer

NCT06054477
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
ALE.C04, Pembrolizumab
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Gilbert, Arizona • Los Angeles, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 10, 2026, 11:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

APG-115 in Salivary Gland Cancer Trial

NCT03781986
View directory record Official record
Conditions
Malignant Salivary Gland Cancer, Salivary Gland Cancer
Interventions
APG-115, Carboplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC

NCT00609219
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
autologous EBV specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer

NCT00301028
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Carboplatin, Paclitaxel, Conventional Surgery, Radiation Therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

DX-8951f in Treating Patients With Metastatic Stomach Cancer

NCT00017212
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
exatecan mesylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Long Beach, California • Denver, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

NCT03758781
View directory record Official record
Conditions
Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma, Urothelial Carcinoma, NSCLC, Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
IRX 2, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 10, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available

Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer

NCT00256295
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Sai-Hong Ignatius Ou
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

NCT00006081
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Bryostatin-1, Paclitaxel (Taxol)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 10, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN

NCT01305772
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Surgery, Radiation Therapy
Drug · Procedure
Lead sponsor
Neal Ready
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

NCT00701857
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, Pemetrexed, radiation therapy
Drug · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 10, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

NCT01697800
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 10, 2026, 11:47 PM EDT
Completed No phase listed Observational

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

NCT04027543
View directory record Official record
Conditions
Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma, Effect of Drugs, Safety Issues
Interventions
Neoadjuvant chemoradiotherapy, Oesophagectomy, Neoadjuvant chemotherapy
Combination Product · Procedure · Drug
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Other
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 10, 2026, 11:47 PM EDT